Examining the dipeptidyl peptidase-IV inhibitory potential of phytochemicals from Calophyllum inophyllum: an in silico study

Read full text
Authors: Felix O. Gboyero, Esther Aina Olanudun, Jeremiah P. Ugwo, Josephine O. Fagbemi, Moses Orimoloye Akinjiyan, Ayomide B. Alimi, Blessing Ibukun Okunribido, F. P. Okunola, Favour Oluwatobi Aremu, Kolade Olatubosun Faloye
Cited by: 1
References: 35

Abstract

Calophyllum inophyllum is a medicinal plant that is extensively used in traditional Chinese medicine. Dipeptidyl peptidase IV is a diabetes mellitus enzyme that inhibits the action of key insulin-stimulating receptors. This study was designed to discover potential DPP IV inhibitors from C. inophyllum . A library of 140 phytochemicals was collated, and molecular docking was performed at exhaustiveness of 100. A 100 ns simulation was performed to examine the ligand’s dynamics and stability, while the selected phytochemicals’ ADMET properties were profiled using the pkCSM web server. Calanone (-10.2 kcal/mol), inophyllolide (-9.4 kcal/mol), brasilixanthone B (-9.4 kcal/mol), calozeyloxanthone (-9.4 kcal/mol), and calophyllin B (-9.4 kcal/mol) were identified as hit molecules against the receptor. The RMSD, RMSF, and interaction plots obtained from the molecular dynamics simulation showed that the phytochemicals exhibited good stability, while the ADMET profiling indicated that the ligands exhibited good drug candidacy properties. The study indicated that calanone, inophyllolide, brasilixanthone B, calozeyloxanthone, and calophyllin B are among the major antidiabetic compounds in C. inophyllum . A comprehensive in vitro and in vivo study is recommended for further studies.

Fields of Study & Subjects

Natural Compound Pharmacology Studies Peptidase Inhibition and Analysis Diabetes Treatment and Management

Publication details

Journal / source
In Silico Research in Biomedicine
Publisher
Elsevier BV
Volume
2
Pages
100183–100183
Publication date
1 January 2026
Language
EN